Atossa Therapeutics Files 8-K
Ticker: ATOS · Form: 8-K · Filed: Nov 4, 2024 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.18 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: ATOS
TL;DR
ATOS filed an 8-K on 11/4, check for 'Other Events' details.
AI Summary
On November 4, 2024, Atossa Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing signifies that Atossa Therapeutics has reported an event to the SEC, which could be routine or material, requiring investors to check the full document for details.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification without specific material disclosures, thus posing a low immediate risk.
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- November 4, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 206.588.0256 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Atossa Therapeutics?
The primary purpose of this 8-K filing is to report "Other Events" as of November 4, 2024.
When was this 8-K report filed?
This 8-K report was filed on November 4, 2024.
In which state is Atossa Therapeutics, Inc. incorporated?
Atossa Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Atossa Therapeutics?
The address of the Principal Executive Offices is 10202 5th Avenue NE, Suite 200, Seattle, Washington 98125.
Does the filing excerpt mention any specific financial transactions or material events?
No, the provided excerpt of the 8-K filing does not detail any specific financial transactions or material events, only indicating 'Other Events'.
Filing Stats: 426 words · 2 min read · ~1 pages · Grade level 12.7 · Accepted 2024-11-04 06:35:08
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
Filing Documents
- atos-20241104.htm (8-K) — 41KB
- atos-ex99_1.htm (EX-99.1) — 24KB
- img248274862_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-120268.txt ( ) — 204KB
- atos-20241104.xsd (EX-101.SCH) — 28KB
- atos-20241104_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events On November 4, 2024, Atossa Therapeutics, Inc. issued a press release announcing positive topline data from the KARISMA-Endoxifen Phase 2 study of (Z)-endoxifen in premenopausal women with mammographic breast density (MBD). A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference. Exhibits Exhibit Number Description of Exhibit 99.1 Press release, dated November 4, 2024 104 Cover page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: November 4, 2024 By: /s/ Heather Rees Chief Financial Officer